![vray trial vray trial](https://www.visual-eyes-media.co.uk/wp-content/uploads/2018/03/tester_Photo-27.jpg)
It's important to always anchor on two critical customer desires. Beyond financial results, we continue solid execution on our clinical innovation and commercial pipelines. Finally, from a cash perspective, we used approximately $17 million in the quarter and ended with $150 million of cash on hand. All of this growth was achieved while keeping operating expenses roughly flat. Total gross margin for the quarter was 10%, an increase of 2,100 basis points over prior year. Revenue was $19 million for the quarter, based primarily on three revenue units. Our backlog grew $56 million or 24% over prior year and now stands at $295 million. We have received more orders in the first nine months of 2021 than all 12 months in 2020. This quarter, we delivered another seven MRIdian orders versus four in Q3 2020. We continue to have solid financial performance in 2021. Let's begin with our Q3 results on Slide 4. This growing body of data is vital to our efforts to change and improve the paradigm of care. Our customers have initiated over 60 clinical trials. About 16,000 patients have been treated on MRIdian, thousands of them with clinically reported outcomes that are consistent and compelling.Ĭlinical curiosity on our system is remarkable. We now have 46 MRIdian systems installed and over 50 in backlog. Our mission is to treat improve what others can't. If you're not on the webcast, I'll be referring to slides from the presentation on our Investor Relations site. Zach will cover our financial results, and then we look forward to answering your questions. Today, we will begin with key patient metrics, then discuss our third quarter results and recent events We'll share exciting progress in our clinical and innovation pipelines. Good afternoon, everyone, and welcome to our Q3 call. Scott Drake - President and Chief Executive Officer
#VRAY TRIAL UPDATE#
ViewRay undertakes no obligation to revise or otherwise update any statements to reflect events or circumstances after the date of this call. Furthermore, the content of this conference call contains time-sensitive information accurate only as of today, November 4, 2021. For a description of these risks and uncertainties, please see ViewRay annual report on Form 10-K for the fiscal year ended December 31, 2020, and in its quarterly reports on Form 10-Q as updated periodically with the company's other SEC filings.